Shikonin reduced the extracellular secretion of PKM2 by inhibiting the binding of GP73 and PKM2, thus further enhancing the inhibitory effect of sorafenib on angiogenesis and M2 macrophage polarization and improving the anti-tumor effect of sorafenib. Here, PKM is linked to neoplasm.